Metastatic Lung Cancer with Jared M. Weiss, MD: Case 2

Video

Metastatic Lung Cancer with Jared M. Weiss, MD

Weiss case 2:

A 62 year-old neversmoker with stage IV adenocarcinoma

  • Mutation testing showed an EGFR exon 19 mutation
  • The patient was treated with erlotinib for 1 year; he developed diarrhea and rash which was successfully managed
  • After 3 months, his disease showed progression on CT; he remained without symptoms.
  • He subsequently developed cough and shortness of breath, correlated to progression of a centrally located lung lesion on his follow up CT scan
  • Repeat biopsy and molecular testing of the central lesion showed EGFR T790M-positivity
  • He was switched to osimertinib therapy and achieved a partial response
  • The patient reported dramatic improvement in his well-being
Related Videos
Video 2 - "Setting Expectations + First-Line and Second-Line Treatment of Graft Versus Host Disease"
Video 1 - "Patient Case: Pathology of Graft Versus Host Disease"
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC

Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC

April 16th 2024
Article

At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).

Read More

FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

March 15th 2024
Podcast

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Listen

Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC

Evolving Treatment Paradigms with Amivantamab in Wild-Type NSCLC

April 12th 2024
Article

Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the 2024 American Association for Cancer Research Annual Meeting.

Read More

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

December 15th 2023
Podcast

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Listen

Understanding ADC Mechanism of Action Enhances Personalized Medicine in NSCLC

Understanding ADC Mechanism of Action Enhances Personalized Medicine in NSCLC

April 8th 2024
Article

There is currently 1 FDA-approved antibody-drug conjugate available for patients with non-small cell lung cancer, and several more potentially coming down the pike.

Read More

Schneider Urges Closer Review of Mechanisms of Resistance in Relapsed NSCLC

Schneider Urges Closer Review of Mechanisms of Resistance in Relapsed NSCLC

April 7th 2024
Article

Though osimertinib is the preferred frontline approach to treatment for those with non-small cell lung cancer with classic EGFR mutations, acquired resistance mechanisms invariably develop.

Read More